TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387

AUSTIN, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that its President and CEO, Glenn Mattes, will be available for one-on-one meetings and will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:00pm EST.

TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference

The shares of TFFP have slumped, most likely as a result of disappointment over an absence of a deal with one of the top mRNA vaccine producers. However, besides a host of programs developed alone or with partners, the TFF platform remains very relevant for both vaccines as well as therapeutics combating Covid.

TFF Pharma's Platform Is Highly Relevant In The Battle Against The Pandemic

TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.

TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study

Inhaled Tacrolimus Powder Achieves Systemic Therapeutic Drug Levels  Anticipate Additional Safety Data in 3Q 2021  Initiation of Lung Transplant Study Expected in 2H 2021

TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrolimus Inhalation Powder

Augmenta Bioworks and TFF Pharmaceuticals Inc (NASDAQ: TFFP) have selected AUG-3387 as the first lead monoclonal antibody for clinical development against COVID-19 under their joint development Collaboration Agreement.  AUG-3387 will be developed as an inhaled therapy for the treatment of COVID-19 disease.

TFF Pharma, Augmenta Bioworks Select Lead Antibody Program To Develop For COVID-19

AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants

Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19

TFFP has a thin-film technology that produces inhalable powdered forms of common drugs, with various advantages over existing methods.

TFF Pharmaceuticals: Looking Attractive At These Prices

AUSTIN, Texas, May 25, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:30am EST.

TFF Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference

TFF Pharmaceuticals' (TFFP) CEO Glenn Mattes on Q1 2021 Results - Earnings Call Transcript

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals reports first quarter 2021 financial results and provides business update. Conference call today at 4:30pm EDT.

TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals to hold first quarter 2021 financial and business results conference call on May 13, 2021 at 4:30 PM EDT

TFF Pharmaceuticals to Hold First Quarter 2021 Financial and Business Results Conference Call on May 13, 2021

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #DARPA--TFF Pharmaceuticals awarded contract under DARPA's Next-Generation Personalized Protective Biosystems Program for U.S. warfighters.

TFF Pharmaceuticals Awarded Contract under DARPA's Next-Generation Personalized Protective Biosystems Program for U.S. Warfighters

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP--TFF Pharmaceuticals prices offering of common stock

TFF Pharmaceuticals Prices Offering of Common Stock

The company's generic technology provides important benefits and is applicable in a wide range of situations. The company has two dozen shots at goal and is still adding.

TFF Pharmaceuticals: Not A Matter Of If, But When The Shares Will Run Much Higher

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q4 2020 Results - Earnings Call Transcript

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals (NASDAQ: TFFP), reports Fourth Quarter and Full Year 2020 financial and business results. Conference call today at 4:30pm EST.

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results

RADNOR, Pa. and AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement).

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

MEDFORD, Mass. and AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- Two biotech companies have partnered for feasibility studies aimed at opening broader global vaccine distribution through production of a shelf-stable powder form of messenger RNA Covid-19 vaccine that would be easily reconstituted prior to injection and not require the extreme cold chain of current RNA vaccines.

Feasibility Arrangement for shelf-stable powder form of messenger RNA COVID-19 Vaccine Candidate announced by GreenLight Biosciences and TFF Pharmaceuticals

TFF Pharmaceuticals (TFFP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for TFF Pharmaceuticals (TFFP)

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP--TFF Pharmaceuticals to Present at the upcoming H.C. Wainwright Global Life Sciences Conference and the 33rd Annual ROTH Conference in March.

TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #tacrolimus--TFF Pharmaceuticals provides update on its clinical development programs for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.

TFF Pharmaceuticals Provides Update on Clinical Development Programs

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals to hold its fourth quarter and full-year 2020 financial results and business results conference call on March 10, 2021.

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2020 Financial Results and Business Results Conference Call on March 10, 2021

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #Ebola--TFF Pharmaceuticals reports positive preclinical results with two biodefense countermeasures for the Army's USAMRIID laboratories.

TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, will participate in the 2021 BIO CEO & Investor Digital Conference, being held virtually on February 16-18, 2021. Glenn Mattes, President & CEO of TFF Pharmaceuticals, is scheduled to give a pre-recorded company presentation at the confere

News for TFF Pharmaceuticals Stock (TFFP)